Input of the Use of Indometacin in Gitelman Syndrome as Compared to Potassium Sparing Diuretics

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Gitelman syndrome is a rare renal disease where the kidneys are unable to normally retain some salts (sodium, potassium and magnesium). Main consequences of these renal leaks of salts are a tendency toward low blood pressure, hypokalemia and hypomagnesemia both contributing to cardiac and muscles symptoms.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Amiloride; Diuretics; Diuretics, Potassium Sparing; Eplerenone; Indomethacin; Sodium Channel Blockers

Criteria

Inclusion Criteria:

• patients 18-60 yrs old, both sex, with genetically proven Gitelman's syndrome, under birth pill control for woman.

Exclusion Criteria:

• counter-indication to treatment under study

• Other diuretic or NAIS treatments than amiloride, spironolactone, or indometacin